A phase III randomized open-label study comparing gemcitabine plus cetuximab (IMC-C225) versus gemcitabine as first-line therapy of patients with advanced pancreas cancer.
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Cetuximab (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 06 Jul 2010 Results published in JCO.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History